T Cells are the body’snatural defenders against pathogens.  In the past they have been reprogrammed to recognize specific surface antigens of cancer cells to attack and destroy them. The approach has worked well against a variety of cancers. The limitation is that they addition of genetic material is limited by transfer techniques.  This episode of the Talking Biotech Podcast discusses the new approach with Dr. Ken Drazan of Arsenal Bio. They have devised a strategy to place genetic material into T-cells from an afflicted patient that can now work against the disease in question. The approach uses gene editing, adding genetic material to T cells that allows them to recognize specific antigens, such as those associated with ovarian cancer.Follow on Twittter:  @ArsenalBio# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.